 FLORHAM PARK, N.J., Aug. 09, 2021 GLOBE NEWSWIRE -- Cellectar Biosciences, Inc. NASDAQ: CLRB, a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced financial results for the second quarter ended June 30, 2021 and provided a corporate update. 